MedPath

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

Not Applicable
Completed
Conditions
Gingival Recession
Registration Number
NCT04260152
Lead Sponsor
Geistlich Pharma AG
Brief Summary

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

Detailed Description

This double blind, randomized, split mouth study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for the treatment of Miller Class I or II recession defects at 6 months post treatment.

A total sample size of 30 subjects (n=30) will be evaluated at 3 centers with 4 investigators. Power analysis based on 80% power and past McGuire/ Scheyer matched-pair defect recession coverage studies, with one-sided confidence interval 0.025, indicates that in order to detect a 12% difference in root coverage with ± 15% standard deviation a patient sample of 25 should be used . Given the multi-center nature of this study and the intention to follow patients long-term, with normal attrition, 30 subjects will ensure adequate long-term follow-up and provide a "power buffer" for any outcome differences that might be seen between centers.

30 Patients with Miller Class I or II recession defects on bilateral sites will be treated randomly with coronally advanced flap (CAF) in combination with either Geistlich Fibro-Gide (GFG =Test) on one side, and Connective Tissue Graft (CTG = Control) on the contralateral side of the mouth. Follow-up visits after visit 2 surgery will be conducted at week 1,2, 4,12 and 24 and in the long term after 1,3 and 5 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • 18 to 75 years of age, inclusive.
  • Subjects must have at least two teeth with buccal Miller Class I or II recession type defects, 3 mm deep and 3 mm wide on the same tooth in the contralateral quadrant of the same jaw
  • Defects should be similar in size and morphology
  • Teeth with root canals should be asymptomatic, completed at least 6 months prior
  • At least 1mm KT
  • Subjects with parafunctional habits must wear a bite guard to be included.
Exclusion Criteria
  • Participation within the previous 30 days in other investigational clinical trials.
  • Class V restorations or abfractions that obliterate the CEJ.
  • Subjects whose teeth have extremely prominent root surfaces -greater than 2mm facially to the adjacent teeth measured at the level of the CEJ.
  • Systemic conditions that could influence wound healing or any other conditions that would preclude periodontal surgery.
  • Taking medications that compromise wound healing.
  • Acute infectious lesions in the areas intended for surgery.
  • Untreated moderate to severe periodontal disease.
  • Weekly or more frequent use of nicotine products within the past 6 months.
  • Females who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control.
  • Subjects who require sedation in order to undergo surgery.
  • Molars, teeth with axial mobility or interproximal loss of attachment, or full coverage crowns or veneers do not qualify.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in percent root coverage6 months post-treatment

Change in percent root coverage compared to baseline

Secondary Outcome Measures
NameTimeMethod
Patient Reported Outcome (PRO) -Questionnaire: for surgical preference1, 2, 4, 12 weeks, 6 months, 1, 3, 5 years post-treatment

Post-Op PRO questionnaire, Surgival procedure Preference, patients will be asked by a 3rd party recorder, Overall which treatment did you prefer? A or B

Assessment of Wound Healing1, 2, 4, 12 weeks post-treatment

Judgement of soft tissue wound healing after surgery at Visits 3-6; presence of Swelling (yes/ no),

Patient Reported Outcome (PRO) -Patient Diary: Discomfort7 days after surgery starting 1 day after surgery

Post-Op PRO Discomfort Diary completed by Patients at home; scale 0-10, 0=no pain or discomfort at all, 10=as much as you can imagine,

Safety Endpoints: number and frequency of (S)AEs over all and by organ class1, 2, 4, 7, 12 and 24 weeks and year 1,3 and 5 post treatment

Assessment of (S)AEs starting at Visit 2, Surgery

General Periodontal Examination (GPE)baseline (day 0) and 6 months; 1, 3, 5 years post-treatment

change of GPE at various visits compared to baseline, scoring codes 0-4

Safety endpoints: Concomitant Medication1, 2, 4, 12 weeks, 6 months, 1, 3, 5 years post-treatment

Use of Concomitant medication Review: Type of concomitant Medication used.

Overall Duration of Treatment Surgery2-6 hours at day of surgery

Interval from surgery start until surgery end in Hours/Minutes

Patient Reported Outcome (PRO) -Questionnaire: Esthetics6 months, 1, 3, 5 years post-treatment

Post-Op PRO questionnaire, Esthetics and overall satisfaction, patients will be asked by a 3rd party recorder, scale 0-10, 0=not satisfied at all with estehtic appearance, 10=completely satisfied,

Trial Locations

Locations (3)

Seven Lakes Periodontitis

🇺🇸

Fenton, Michigan, United States

Perio Health Professionals

🇺🇸

Houston, Texas, United States

Oral Health Specialists

🇺🇸

Tacoma, Washington, United States

Seven Lakes Periodontitis
🇺🇸Fenton, Michigan, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.